THE TALK: Breast Cancer - Episode 3

Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial

, , ,

Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.

EP. 1: Updates in HER2+ Breast Cancer from ESMO 2021
EP. 2: Interesting Trials in HER2+ Breast Cancer
Now Viewing
EP. 3: Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial
EP. 4: ESMO 2021: Updates in Triple Negative Breast Cancer

Data from the following clinical trial are discussed:

  • LBA17_PR - Overall survival (OS) results from the phase 3 MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)